Companion diagnostics

Closer pathology-oncology care team coordination is key to leverage the value of precision therapies and improve outcomes

How companion diagnostic tests are helping cancer patients find personalized answers – and treatments – fast

Users share their experiences with the Ion Torrent™ Genexus™ platform over the two years since the technology was introduced to the lab community

David Rimm continues the conversation about the best assay for atezolizumab after a recent response to his original article

Emina Torlakovic and Allen Gown share their disagreements with David Rimm’s comments about an FDA-approved PD-L1 assay for atezolizumab

Not every assay that trials well is practical for implementation in daily practice. How can we tell which ones are, and whose responsibility is it?

A response to David Rimm’s letter that supports the role of PD-L1 testing in improving outcomes for cancer patients.

David Rimm challenges the sensitivity and reproducibility of a new assay for PD-L1 detection.

Liquid biopsy can help us appropriately treat patients with anti-PD-L1 immunotherapies, and ddPCR enables ongoing monitoring and adjustment of treatment

An efficient alternative to pap-HPV tests could lie with ddPCR and a ccfDNA assay